(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)
Health
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Audio By Carbonatix
(Reuters) -Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Verve is developing therapies targeting genes that regulate cholesterol in the liver.
(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)